Press Releases April 27, 2026 04:05 PM

InspireMD to Announce First Quarter 2026 Financial Results

InspireMD announces upcoming Q1 2026 financial results release and conference call

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
NSPR

InspireMD, Inc., a developer of carotid stent systems utilizing MicroNet mesh technology, will release its financial results for the first quarter of 2026 on May 4, 2026. The company will host a webcast and conference call to discuss these results and recent developments.

InspireMD to Announce First Quarter 2026 Financial Results
NSPR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • InspireMD will release Q1 2026 financial results on May 4, 2026.
  • A conference call and webcast will be held to discuss financial results and company updates.
  • The company aims to make its MicroNet mesh technology the standard in carotid stenting to improve stroke prevention outcomes.

MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its first quarter financial results on Monday, May 4, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live audio webcast and an archive of the recording will be available here and through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com. Interested participants are encouraged to register more than 15 minutes before the start of the call.

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR.

We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

Investor Contact:
Jeff Warren
LifeSci Advisors
[email protected]
[email protected]


Risks

  • Uncertainty about specific financial performance as detailed results have not yet been released.
  • Potential challenges in adoption and competition within the medical devices and stroke prevention technology sector.
  • Dependence on regulatory approvals and healthcare reimbursement environments impacting product sales and market penetration.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026